Synonyms: SPR-719 | VXc-486
Compound class:
Synthetic organic
Comment: SPR719 is a novel aminobenzimidazole antibacterial compound that is a dual Inhibitor of bacterial DNA gyrase and DNA topoisomerase 4 [1]. An orally administered prodrug, fobrepodacin (SPR720), is being developed for the treatment of non-tuberculous mycobacterial pulmonary disease (NTM-PD).
|
|
References |
1. Grillot AL, Le Tiran A, Shannon D, Krueger E, Liao Y, O'Dowd H, Tang Q, Ronkin S, Wang T, Waal N et al.. (2014)
Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability. J Med Chem, 57 (21): 8792-816. [PMID:25317480] |
2. Locher CP, Jones SM, Hanzelka BL, Perola E, Shoen CM, Cynamon MH, Ngwane AH, Wiid IJ, van Helden PD, Betoudji F et al.. (2015)
A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother, 59 (3): 1455-65. [PMID:25534737] |
3. Talley AK, Thurston A, Moore G, Gupta VK, Satterfield M, Manyak E, Stokes S, Dane A, Melnick D. (2021)
First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of SPR720, a Novel Oral Bacterial DNA Gyrase (GyrB) Inhibitor for Mycobacterial Infections. Antimicrob Agents Chemother, 65 (11): e0120821. [PMID:34491803] |